Loading...

Brilliant Violet 605™ anti-mouse/human CD11b Antibody

Pricing & Availability
Clone
M1/70 (See other available formats)
Regulatory Status
RUO
Other Names
αM integrin, Mac-1, Mo1, CR3, Ly-40, C3biR, ITGAM
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
M1slash70_BV605_020212
C57BL/6 mouse bone marrow cells were stained with CD11b (clone M1/70) Brilliant Violet 605™. Data shown was gated on myeloid cell population.
  • M1slash70_BV605_020212
    C57BL/6 mouse bone marrow cells were stained with CD11b (clone M1/70) Brilliant Violet 605™. Data shown was gated on myeloid cell population.
Compare all formats See Brilliant Violet 605™ spectral data
Cat # Size Price Quantity Check Availability Save
101237 125 µL 168€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
101257 50 µg 206€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD11b is a 170 kD glycoprotein also known as αM integrin, Mac-1 α subunit, Mol, CR3, and Ly-40. CD11b is a member of the integrin family, primarily expressed on granulocytes, monocytes/macrophages, dendritic cells, NK cells, and subsets of T and B cells. CD11b non-covalently associates with CD18 (β2 integrin) to form Mac-1. Mac-1 plays an important role in cell-cell interaction by binding its ligands ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, and fibrinogen.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse, Human, Cynomolgus, Rhesus
Reported Reactivity
Chimpanzee, Baboon, Rabbit
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C57BL/10 splenocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For flow cytometric staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone M1/70 has been verified for immunocytochemistry (ICC) and frozen immunohistochemistry (IHC-F).

Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1,4, in vitro blocking3,9,12, depletion2,8, immunofluorescence microscopy6,7,10, immunohistochemistry of acetone-fixed frozen sections5,11-13, and spatial biology (IBEX)35,36. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) (Cat. No. 101248).

Application References

(PubMed link indicates BioLegend citation)
  1. Springer T, et al. 1978. Eur. J. Immunol. 8:539. (IP)
  2. Ault K and Springer T. 1981. J. Immunol. 126:359. (Deplete)
  3. Springer TA, et al. 1982. Immunol. Rev. 68:171. (Block)
  4. Ho MK and Springer TA. 1983. J. Biol. Chem. 258:2766. (IP)
  5. Flotte TJ, et al. 1983. Am. J. Pathol. 111:112. (IHC)
  6. Noel GJ, et al. 1990. J. Clin. Invest. 85:208. (IF)
  7. Allen LA and Aderem A. 1996. J. Exp. Med. 184:627 (IF)
  8. D'Amico A and Wu L. 2003. J. Exp. Med. 198:293. (Deplete)
  9. Brickson SJ, et al. 2003. Appl Physiol. 95:969. (Block)
  10. Clatworthy MR and Smith KG. 2004. J. Exp. Med. 199:717. (IF)
  11. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  12. Zhang Y, et al. 2002. J. Immunol. 168:3088. (IHC)
  13. Iwasaki A and Kelsall BL. 2001. J. Immunol. 166:4884 (IHC, FC)
  14. Tailleux L. 2003. J. Exp. Med. 197:121. (Block, FC)
  15. Olver S, et al. 2006. Cancer Research 66:571. (FC)
  16. Tan SL, et al. 2006. J. Immunol. 176:2872. (FC) PubMed
  17. Ponomarev ED, et al. 2006. J. Immunol. 176:1402. (FC)
  18. Dzhagalov I, et al. 2007. Blood 109:1620. (FC)
  19. Fazilleau N, et al. 2007. Nature Immunol. 8:753.
  20. Rasmussen JW, et al. 2006. Infect. Immun.74:6590. PubMed
  21. Napimoga MH, et al. 2008. J. Immunol. 180:609. PubMed
  22. Elqaraz-Carmon V, et al. 2008. J. Lipid. Res. 49:1894. PubMed
  23. Kim DD, et al. 2008. Blood 112:1109. PubMed
  24. Guo Y, et al. 2008. Blood 112:480. PubMed
  25. Norian LA, et al. 2009. Cancer Res. 69:3086. (FC) PubMed
  26. Baumgartner CK, et al. 2010. J. Immunol. 184:573. PubMed
  27. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  28. Whiteland J, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
  29. Weber GF, et al. 2014. J Exp Med. 211:1243. PubMed
  30. Ashok A, et al. 2015. Toxicol Sci. 143:64. PubMed
  31. Price PJ, et al. 2015. J Immunol. 194:1164. PubMed
  32. Doni A, et al. 2015. J Exp Med. 212:905. PubMed
  33. Ferreira R, et al. 2016. J Infect Dis. 213: 669 - 673. PubMed
  34. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  35. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  36. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Michela Miani et al. 2018. Cell metabolism. 28(4):557-572 . PubMed
  2. Tran NT, et al. 2019. Cell Rep. 28:3510. PubMed
  3. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  4. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  5. Iwahori K, et al. 2019. Sci Rep. 2.205555556. PubMed
  6. Garber C, et al. 2019. Nat Neurosci. 1.802777778. PubMed
  7. Harapas CR, et al. 2022. Sci Immunol. 7:eabi4611. PubMed
  8. Christian DA, et al. 2022. Sci Immunol. 7:eabq7432. PubMed
  9. Bonifacio JPPL, et al. 2022. J Virol. 96:e0087122. PubMed
  10. Skladanowska K, et al. 2022. Cell Rep. 41:111490. PubMed
  11. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  12. Jia DJ, et al. 2022. Gut Microbes. 14:2145843. PubMed
  13. Chen LC, et al. 2023. Immunology. 169:271. PubMed
  14. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  15. Zhang AQ, et al. 2023. Nat Biomed Eng. . PubMed
  16. Oh J, et al. 2023. Nat Commun. 14:3278. PubMed
  17. Marchelletta RR, et al. 2021. J Clin Invest. 131:. PubMed
  18. Pohlmeier L, et al. 2021. Allergy. 76:2030. PubMed
  19. Duraiswamy J, et al. 2021. Cancer Cell. 39:1623. PubMed
  20. Xin B, et al. 2022. Hepatology. 76:630. PubMed
  21. Alam A, et al. 2022. Cancer Cell. 40:153. PubMed
  22. McCauley KE, et al. 2022. Cell Rep Med. 3:100713. PubMed
  23. Mansouri S, et al. 2022. J Immunol. 209:2114. PubMed
  24. Cousin N, et al. 2022. Cells. 12: . PubMed
  25. Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed
  26. Dickerson KM, et al. 2022. Blood Cancer Discov. 3:240. PubMed
  27. Gallizioli M, et al. 2020. Cell Rep. 33:108291. PubMed
  28. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  29. Jong RM, et al. 2022. J Immunol. 208:407. PubMed
  30. Boal-Carvalho I, et al. 2020. EMBO Rep. 21:e50421. PubMed
  31. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  32. Rosenheinrich M, et al. 2015. PLoS One. 10: 0136290. PubMed
  33. Herz J, et al. 2015. J Exp Med. 212: 1153 - 1169. PubMed
  34. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  35. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  36. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
  37. Frank AC, et al. 2021. Theranostics. 11:7570. PubMed
  38. Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed
  39. Song J, et al. 2021. J Am Heart Assoc. 10:e017329. PubMed
  40. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  41. Hu J, et al. 2021. Sci Adv. 7:. PubMed
  42. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
  43. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  44. Bauer KM, et al. 2022. JCI Insight. 7:. PubMed
  45. Morris MG, et al. 2020. Comp Med. 70:336. PubMed
  46. Piper CJM, et al. 2020. Cell Reports. 29(7):1878-1892.e7.. PubMed
  47. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  48. Tordesillas L, et al. 2018. Nat Commun. 9:5238. PubMed
  49. Bratti M, et al. 2022. Front Immunol. 13:1029759. PubMed
  50. Huard A, et al. 2021. J Immunol. 206:1058. PubMed
  51. Chen WS, et al. 2021. Cell Rep. 37:109974. PubMed
  52. Han Y et al. 2019. Cell reports. 27(3):835-846 . PubMed
  53. Christopher S Garris et al. 2018. Immunity. 49(6):1148-1161 . PubMed
  54. Chan YH, et al. 2019. EMBO Mol Med. 11:e10092. PubMed
  55. Gómez-Díaz C, et al. 2021. iScience. 24:103241. PubMed
  56. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  57. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  58. Webster HC, et al. 2020. J Immunol Methods. 112702:477. PubMed
  59. Macpherson L, et al. 2020. Nature. 577:266. PubMed
  60. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  61. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  62. Dieterich LC, et al. 2019. International Journal of Cancer. 145(10):2804-2815. PubMed
  63. Wang C, et al. 2021. Cell Stem Cell. . PubMed
  64. Niss K, et al. 2020. Cell Reports. 31(11):107763. PubMed
  65. Ruhland MK, et al. 2020. Cancer Cell. 37(6):786-799.e5. PubMed
  66. Iannello A, et al. 2013. J Exp Med. 210:2057. PubMed
  67. Linehan JL et al. 2018. Cell. 172(4):784-796 . PubMed
  68. Bonnardel J, et al. 2019. Immunity. 51:638. PubMed
  69. Dar HH, et al. 2022. JCI Insight. 7:. PubMed
  70. Li Y, et al. 2022. J Neuroinflammation. 19:261. PubMed
  71. Ray A, et al. 2015. PLoS One. 10: 0137314. PubMed
  72. McBride KM, et al. 2019. Front Oncol. 9:517. PubMed
  73. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  74. Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed
  75. Campbell C et al. 2018. Immunity. 48(6):1245-1257 . PubMed
  76. Stotesbury C, et al. 2020. J Immunol. 204:1582. PubMed
  77. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  78. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  79. Martínez‐López M et al. 2019. Immunity. 50(2):446-461 . PubMed
  80. Yang H, et al. 2019. J Neuroinflammation. 16:169. PubMed
  81. Sun T, et al. 2017. Mucosal Immunol. 0.954861111. PubMed
  82. Branchett WJ, et al. 2020. Wellcome Open Research. 0.278472222. PubMed
  83. Yang C, et al. 2022. Research (Wash D C). 2022:9768687. PubMed
  84. Aktories P, et al. 2022. Cell Rep Methods. 2:100260. PubMed
  85. Deerhake ME, et al. 2021. Immunity. 54(3):484-498.e8. PubMed
  86. Cohen M et al. 2018. Cell. 175(4):1031-1044 . PubMed
  87. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  88. Dudeck J, et al. 2019. J Allergy Clin Immunol. 143:1849. PubMed
  89. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  90. Wang YT, et al. 2020. Nat Microbiol. 0.397222222. PubMed
  91. Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed
  92. Godwin MS, et al. 2019. JCI Insight. 4:e126070. PubMed
  93. Pinho–Ribeiro FA, et al. 2018. Cell. 173:1083. PubMed
  94. Rive CM, et al. 2022. Mol Ther Methods Clin Dev. 26:4. PubMed
  95. Hamaidi I, et al. 2020. Cell Metabolism. 32(3):420-436.e12. PubMed
  96. Mansouri S, et al. 2020. Mucosal Immunol. 0.954861111. PubMed
  97. Goh W, et al. 2020. Cell Rep. 33:108285. PubMed
  98. Swanson P, et al. 2016. PLoS Pathog. 12:e1006022. PubMed
  99. Macal M et al. 2018. Immunity. 48(4):730-744 . PubMed
  100. Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed
  101. Yousef H, et al. 2019. Nat Med. 25:988. PubMed
  102. Rosser EC, et al. 2020. Cell Metabolism. 31(4):837-851. PubMed
  103. Luo M, et al. 2021. J Immunol. 207:1683. PubMed
  104. Shi H, et al. 2015. Nat Immunol. . PubMed
  105. Zhu YP et al. 2018. Cell reports. 24(9):2329-2341 . PubMed
  106. Li N, et al. 2022. Nat Commun. 13:7281. PubMed
  107. Nam J, et al. 2021. Adv Ther (Weinh). 4:. PubMed
  108. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  109. Montalban-Arques A, et al. 2021. Cell Host Microbe. :. PubMed
  110. Xu C, et al. 2020. Immunity. 53(2):417-428.e4. PubMed
  111. Frank AC, et al. 2019. Nat Commun. 10:1135. PubMed
  112. Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed
  113. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  114. Melhem NJ, et al. 2021. Circulation. 143:566. PubMed
  115. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  116. Crichton M, et al. 2016. Sci Rep. 6:27217. PubMed
  117. White JP et al. 2018. Cell. 175(5):1198-1212 . PubMed
  118. Seenappa LM, et al. 2022. NPJ Vaccines. 7:128. PubMed
  119. Rosen SF, et al. 2022. Genome Med. 14:108. PubMed
  120. Stotesbury C, et al. 2020. Aging Cell. 19:e13170. PubMed
  121. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  122. O'Boyle C, et al. 2020. Int J Stroke. 0.746527778. PubMed
  123. Lai NY, et al. 2020. Cell. 180:33:00. PubMed
  124. Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed
  125. Rivera CA, et al. 2022. Immunity. 55:129. PubMed
  126. Wang T, et al. 2015. Proc Natl Acad Sci U S A. 112:440. PubMed
  127. Sparber F et al. 2019. British journal of pharmacology. 176(11):1728-1744 . PubMed
  128. Bretou M, et al. 2017. Sci Immunol. 2:16. PubMed
  129. Fearon AE, et al. 2021. iScience. 24:103143. PubMed
  130. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
  131. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
  132. Matei DE, et al. 2021. Med (N Y). 2:864. PubMed
  133. C Khouili S, et al. 2020. Cell Rep. 33:108468. PubMed
RRID
AB_11126744 (BioLegend Cat. No. 101237)
AB_11126744 (BioLegend Cat. No. 101257)

Antigen Details

Structure
Integrin family, associates with integrin β2 (CD18), 170 kD
Distribution

Granulocytes, monocytes/macrophages, dendritic cells, NK cells, subsets of T and B cells

Function
Adhesion, chemotaxis
Ligand/Receptor
ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, fibrinogen
Cell Type
B cells, Dendritic cells, Granulocytes, Macrophages, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Springer TA. 1994. Cell 76:301.
3. Coxon A, et al. 1996. Immunity 5:653.

Gene ID
16409 View all products for this Gene ID 3684 View all products for this Gene ID
UniProt
View information about CD11b on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD11b Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse/human CD11b M1/70 FC
Biotin anti-mouse/human CD11b M1/70 FC
FITC anti-mouse/human CD11b M1/70 FC
PE anti-mouse/human CD11b M1/70 FC,IHC
PE/Cyanine5 anti-mouse/human CD11b M1/70 FC
Purified anti-mouse/human CD11b M1/70 FC,CyTOF®,IP,IHC-F,ICC
PE/Cyanine7 anti-mouse/human CD11b M1/70 FC
Alexa Fluor® 488 anti-mouse/human CD11b M1/70 FC,IHC-F,3D IHC,SB
Alexa Fluor® 647 anti-mouse/human CD11b M1/70 FC,3D IHC,SB
Alexa Fluor® 700 anti-mouse/human CD11b M1/70 FC
Pacific Blue™ anti-mouse/human CD11b M1/70 FC
APC/Cyanine7 anti-mouse/human CD11b M1/70 FC
PerCP/Cyanine5.5 anti-mouse/human CD11b M1/70 FC
PerCP anti-mouse/human CD11b M1/70 FC
Brilliant Violet 421™ anti-mouse/human CD11b M1/70 FC
Brilliant Violet 570™ anti-mouse/human CD11b M1/70 FC
Brilliant Violet 605™ anti-mouse/human CD11b M1/70 FC
Brilliant Violet 650™ anti-mouse/human CD11b M1/70 FC
Brilliant Violet 711™ anti-mouse/human CD11b M1/70 FC
Brilliant Violet 785™ anti-mouse/human CD11b M1/70 FC
Brilliant Violet 510™ anti-mouse/human CD11b M1/70 FC,ICC
Ultra-LEAF™ Purified anti-mouse/human CD11b M1/70 FC,CyTOF®,IP,Block,Depletion,IHC-F,ICC
Purified anti-mouse/human CD11b (Maxpar® Ready) M1/70 FC,CyTOF®
Alexa Fluor® 594 anti-mouse/human CD11b M1/70 IHC-F,FC
PE/Dazzle™ 594 anti-mouse/human CD11b M1/70 FC
APC/Fire™ 750 anti-mouse/human CD11b M1/70 FC
TotalSeq™-A0014 anti-mouse/human CD11b M1/70 PG
Brilliant Violet 750™ anti-mouse/human CD11b M1/70 FC
TotalSeq™-B0014 anti-mouse/human CD11b M1/70 PG
TotalSeq™-C0014 anti-mouse/human CD11b M1/70 PG
Spark NIR™ 685 anti-mouse/human CD11b M1/70 FC
PE/Fire™ 640 anti-mouse/human CD11b M1/70 FC
Spark YG™ 593 anti-mouse/human CD11b M1/70 FC
Spark YG™ 570 anti-mouse/human CD11b M1/70 IHC-F
PE/Fire™ 810 anti-mouse/human CD11b M1/70 FC
APC/Fire™ 810 anti-mouse/human CD11b Antibody M1/70 FC
Spark Blue™ 550 anti-mouse/human CD11b M1/70 FC
Spark UV™ 387 anti-mouse/human CD11b M1/70 FC
PerCP/Fire™ 806 anti-mouse/human CD11b M1/70 FC
PerCP/Fire™ 780 anti-mouse/human CD11b M1/70 FC
Spark Blue™ 574 anti-mouse/human CD11b (Flexi-Fluor™) M1/70 FC
KIRAVIA Blue 520™ anti-mouse/human CD11b M1/70 FC
PE/Fire™ 744 anti-mouse/human CD11b M1/70 FC
Spark PLUS UV395™ anti-mouse/human CD11b M1/70 FC
Spark Red™ 718 anti-mouse/human CD11b (Flexi-Fluor™) M1/70 FC
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account